On April 14, 2026, a California state court dismissed a lawsuit filed by Elevance Health Inc. through its subsidiary Anthem Blue Cross of California against HaloMD and several California‑based providers. The dismissal removes a pending legal challenge that could have exposed the insurer to significant financial penalties and reputational damage.
The suit alleged that HaloMD and the providers had abused the No Surprises Act’s Independent Dispute Resolution (IDR) process, filing more than 1,500 disputes between January 2024 and August 2025, of which roughly 47% were deemed ineligible. Elevance claimed the arbitration outcomes were manipulated to over‑charge patients and providers, and that the IDR process was being used to circumvent statutory protections.
Judge Michael R. Smith ruled that the evidence presented did not establish abuse of the IDR process and that insurers are limited in their ability to seek judicial review of arbitration decisions outside that process. The decision reinforces the finality of IDR determinations and underscores that policy‑based arguments about the IDR framework are better addressed at the legislative level.
Elevance Health’s spokesperson said, 'We strongly disagree with the court's ruling, which was based on a procedural issue and did not address most of our arguments. We believe it misinterprets the No Surprises Act and improperly limits judicial review, and we intend to appeal with confidence in our position.' The insurer has indicated it will file an appeal, signaling that the legal battle remains a priority.
The dismissal is part of a broader wave of litigation over the No Surprises Act. HaloMD, a prominent IDR intermediary, has faced similar lawsuits in other states, and other insurers such as UnitedHealth Group have also challenged arbitration outcomes. In the first half of 2025, the IDR process handled 1.2 million disputed claims, far exceeding the 17,000 claims regulators initially estimated.
For Elevance, the ruling is a setback to its strategy of using litigation to challenge arbitration outcomes. While the dismissal provides short‑term relief from immediate litigation costs, the planned appeal means that legal expenses may persist. The insurer may need to shift focus toward strengthening case preparation and data quality before disputes enter the IDR process, rather than relying on post‑arbitration challenges.
No specific market reaction data were found in the available sources, so the article does not report on investor or analyst responses to the dismissal.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.